Innovation and Translation

EMBL Corporate Partnership Programme

Founded in 2009, the Corporate Partnership Programme connects interested organisations with the latest developments in the molecular life sciences and the world's leading molecular biology researchers.

Designed to create and enhance long-term, effective relationships between EMBL and top-class corporate partners, the programme provides opportunities for partners to draw on EMBL’s excellent track record of collaborations with industry for the co-development of training, products, services, and technology transfer.

Thanks to the generous support of its corporate partners, EMBL can bring talented young scientists to its world-class scientific gatherings, where they contribute to and participate in advanced scientific training. Through this Programme, EMBL and its corporate partners support the development and promotion of innovative and ground-breaking scientific events in Europe.

EMBL-EBI Industry Programme

The EMBL-EBI Industry Programme has been an important and vibrant part of EMBL-EBI since 1996, providing regular contact and interaction with key stakeholders and opinion leaders at major global commercial companies, and informing them of the institute’s future directions.

The programme ─ which includes webinars, quarterly strategy meetings, and expert-level workshops on topics prioritised by members ─ is subscription-based for global companies that make significant use of the data and resources provided by EMBL-EBI as a core part of their R&D. Member companies represent most of the top 20 pharmaceutical companies as well as several major agri-food, nutrition and healthcare companies.

The EMBL-EBI Industry Programme serves as an interface between industry-focussed initiatives at EMBL-EBI and organisations such as Innovative Medicines Initiative (IMI), the Pistoia Alliance, and the Clinical Data Interchange Standards Consortium (CDISC) among others.

EMBLEM

EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) is an affiliate and the commercial arm of the European Molecular Biology Laboratory (EMBL). Established in 1999, EMBLEM identifies, protects and commercialises the intellectual property developed at EMBL, by EMBL alumni and by non-EMBL third parties. EMBLEM works closely with industrial partners in the biotech, IT and engineering markets to accelerate the transfer of innovative technology from basic research to industry.

EMBLEM manages a portfolio of close to 300 individual patents, patent applications, copyrights, trademarks and utility models. The technology portfolio, which spans the life sciences, includes enabling technologies, scientific instruments, molecular tools and techniques, as well as software programmes and databases.

EMBL Ventures

Based in Heidelberg, Germany, EMBL Ventures invest throughout Europe to build companies that create significant commercial opportunities based on new therapeutic-treatment modalities and pharmaceuticals, next-generation enabling-technology platforms or innovations in the diagnostics and medical device area.

As an independent and focused team, EMBL Ventures moves quickly with short decision timelines.